Structured evidence table for Ginkgo Sleep Quality Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ginkgo Sleep Quality Randomized Trial | Conclusion Current RCT evidence shows inconsistent and limited findings, and no firm conclusions can be drawn about whether any OTC therapy provides symptomatic benefit. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Sleep Quality Randomized Trial | Level of evidence 1 (Systematic review of RCTs with low-moderate heterogeneity). | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Sleep Quality Randomized Trial | Objective To review the effectiveness of over-the-counter (OTC) treatments in reducing tinnitus symptom severity as measured by the Tinnitus Handicap Inventory (THI) in randomized controlled trials. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Sleep Quality Randomized Trial | Methods A comprehensive search was conducted in PubMed, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and WHO ICTRP through March 2025. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Sleep Quality Randomized Trial | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Sleep Quality Randomized Trial | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Sleep Quality Randomized Trial | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Sleep Quality Randomized Trial | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
Source documents